Mauna Kea Technologies S.A.

Mauna Kea Technologies is a global medical device company headquartered in Paris, France, specializing in endomicroscopy. The company's core business revolves around real-time in vivo cellular imaging, with a mission to empower physicians and surgeons to diagnose and treat patients with enhanced confidence by democratizing this advanced imaging technology.

The company's flagship product is Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system. This technology provides real-time access to histological information during endoscopy procedures, enabling cellular visualization to monitor disease progression, assess immediate reactions, classify indeterminate areas of concern, and guide surgical interventions. Cellvizio is utilized across various medical specialties, including gastroenterology, pulmonology, urology, neurosurgery, and uro-oncology, and is also being integrated with AI-assisted imaging and robotic surgery.

In recent news, Mauna Kea Technologies reported strong Q1 2026 core sales growth, with a 68% increase, following a comprehensive debt restructuring and reaccelerating organic growth in FY 2025. The company successfully completed a financial restructuring and a €6 million capital raise in November 2025, establishing a stronger financial foundation. Sacha Loiseau, Ph.D., serves as the Founder, Chairman of the Board, and CEO. The company is focused on enhancing precision medicine and aims to achieve EBITDA profitability by the end of 2027, driven by commercial acceleration in key markets and strategic partnerships, such as one with V7 in March 2024 to develop AI applications for Cellvizio.

Latest updates

Mauna Kea Technologies Showcases Broad Clinical Data for Cellvizio at Digestive Disease Week

Event summary

  • Mauna Kea Technologies will present ten abstracts related to Cellvizio® at Digestive Disease Week (DDW) 2026, May 2-5 in Chicago.
  • Presentations will focus on pancreatic cystic lesions, gastric cancer detection, inflammatory bowel disease (IBD) assessment, and food intolerance diagnosis.
  • The CLIMB study, featuring EUS-nCLE data from 526 patients, will be presented at the ASGE Presidential Plenary Session.
  • Mauna Kea Technologies will host a Pancreatic Cyst Consortium Meeting with over 100 interventional endoscopists and a CellTolerance® dinner with key opinion leaders.

The big picture

Mauna Kea Technologies is attempting to establish Cellvizio as a standard-of-care diagnostic tool across several high-prevalence gastrointestinal conditions. The company's reliance on clinical data and partnerships to drive adoption highlights the challenges of introducing novel medical technologies into established clinical workflows. The focus on AI integration signals an attempt to modernize the platform and appeal to a data-driven healthcare landscape.

What we're watching

Clinical Adoption
The success of Cellvizio hinges on widespread adoption by clinicians; the scale of the DDW presentations, particularly the CLIMB study, will be a key indicator of this trend.
AI Integration
The presentation of AI-driven assessment tools for IBD suggests a strategic pivot; whether this integration can meaningfully improve diagnostic accuracy and workflow remains to be seen.
Commercial Dynamics
The joint commercial efforts with TaeWoong Medical USA are crucial for US market penetration; the sustainability of this partnership and its impact on sales will be a critical factor.
CID: 1103